|
|
|
21.08.26 - 05:36
|
8 ASX shares just upgraded by the experts (Fool)
|
|
|
Brokers have increased their ratings on CSL, IAG, Fortescue, A2 Milk, and others this week.
The post 8 ASX shares just upgraded by the experts appeared first on The Motley Fool Australia....
|
|
|
12.08.26 - 12:36
|
Swedish PM Calls Spanish Illegal Immigrant Amnesty ′Very Bad Idea′ (ZeroHedge)
|
|
|
Swedish PM Calls Spanish Illegal Immigrant Amnesty 'Very Bad Idea'
Authored by Guy Birchall via The Epoch Times,
Swedish Prime Minister Ulf Kristersson has called the Spanish government's amnesty for illegal immigrants a "very bad idea," warning that it could spark another migrant crisis akin to the one that beset the continent in 2015.
Swedish Prime Minister Ulf Kristersson in Brussels on Dec. 19, 2024. Johanna Geron/Reuters
The center-right politician, who is running for reelection next month, told the Financial Times in an interview published on Aug. 11 that the Spanish amnesty for more than a million illegal immigrants had caused a "pretty big outcry" at the last summit of EU leaders.
Spanish Prime Minister Pedro Sánchez's government granted a royal decree on April 14, launching the regularization of people living illegally in the country.
The proposal was first presented on Jan. 27 to allow about 500,000 illegal immigrants already living and working in Spain to ob...
|
|
|
10.08.26 - 13:03
|
Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency (GlobeNewswire EN)
|
|
|
BARCELONA, Spain, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the completion of the clinical portion of SPARTA (Study of ProlAstin-C Randomized Therapy with Alpha-1 augmentation; NCT01983241), its phase 3 outcomes study evaluating the clinical efficacy and safety of two dose regimens of Prolastin®-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema associated with alpha-1 antitrypsin deficiency (AATD), also known as alpha-1....
|
|
|
|
|
|
|
|
|
29.07.26 - 14:33
|
FOXO TECHNOLOGIES INC.′S SUBSIDIARY VECTOR BIOSOURCE, INC. ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE FOUR BLOOD COLLECTION CENTERS FROM GRIFOLS BIO SUPPLIES, INC. (GlobeNewswire EN)
|
|
|
WEST PALM BEACH, FL, July 29, 2026 (GLOBE NEWSWIRE) -- FOXO Technologies Inc.'s (OTC: FOXOD/FOXO) ( “FOXO”) subsidiary, Vector BioSource, Inc. (“Vector”) today announced that it has entered into a definitive agreement to acquire four U.S.-based blood collection centers (the “Agreement”) from Grifols Bio Supplies, Inc., a U.S.-based subsidiary of Grifols S.A. The acquisition is intended to provide a proprietary source of bio-products to sell to Vector's customers to augment its existing sourcing model. Furthermore, the new FDA licensure that Vector expects to be required is anticipated to further expand Vector's accessible market....
|
|
|
|
|
28.07.26 - 20:00
|
Grifols H1 Profit Rises 29%; Backs FY26 Outlook (AFX)
|
|
|
MADRID (dpa-AFX) - Grifols S.A. (GRFS) on Tuesday reported higher profit for the first half of 2026, supported by growth in its Biopharma business. The company also reaffirmed its full-year guidan......
|
|
|
|
|
|
|
|
|
|
|
24.07.26 - 07:06
|
Almirall H1 2026 Results (Business Wire)
|
|
|
Almirall delivers solid H1 2026 results growing Net Sales by 7.5% and EBITDA by 23.7%, driven by its strong European Dermatology business – reiterating guidance aligned with long-term growth trajectory
Net Sales increased by 7.5% YoY to €602.7 MM, while EBITDA grew by 23.7% to €150.7 MM, reflecting strong commercial and operational execution.
The European Dermatology business continues to drive growth, increasing 18.1% YoY to €341.9 MM, supported by strong performance of its key growth drivers and favourable underlying market growth.
Continued solid performance of the biologics portfolio, with Ilumetri® delivering 10.5% increase to €125.2 MM and Ebglyss® growing 88.2% to €84.5 MM in Net Sales, supported by sustained growth in recent launch markets.
The broader dermatology portfolio delivers positive performance, including Wynzora® (19.3%, total of €20.4 MM) and Klisyri® (13.9%, total of €15.6 MM).
Almirall advances its innovation strategy through progress across its R&D pipeline, inclu...
|
|
|
|
|
22.07.26 - 06:12
|
TAGESVORSCHAU: Termine am 22. Juli 2026 (DPA-AFX)
|
|
|
FRANKFURT (dpa-AFX) - Wirtschafts- und Finanztermine am Mittwoch, den 22. Juli^TERMINE UNTERNEHMEN06:45 NOR: Equinor, Q2-Zahlen06:50 ESP: Banco Santander, Halbjahreszahlen07:00 CHE: VAT, Halbjahreszahlen07:00 CHE: Lonza, ......
|
|
|
21.07.26 - 17:39
|
TAGESVORSCHAU: Termine am 22. Juli 2026 (DPA-AFX)
|
|
|
FRANKFURT (dpa-AFX) - Wirtschafts- und Finanztermine am Mittwoch, den 22. Juli^TERMINE UNTERNEHMEN06:45 NOR: Equinor, Q2-Zahlen06:50 ESP: Banco Santander, Halbjahreszahlen07:00 CHE: VAT, Halbjahreszahlen07:00 CHE: Lonza, ......
|
|
|
16.07.26 - 14:03
|
Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins (GlobeNewswire EN)
|
|
|
BARCELONA, Spain, July 16, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced that the first patients have been dosed in two separate Phase 3 trials aiming to expand the U.S. labels for its signature immunoglobulin therapeutics, GAMUNEX®-C, an intravenous immunoglobulin (IVIg), and XEMBIFY®, its subcutaneous immunoglobulin (SCIg)....
|
|
|
08.07.26 - 14:03
|
ORYZON Announces U.S. Patent Grant for Vafidemstat in Borderline Personality Disorder (BPD) (GlobeNewswire EN)
|
|
|
MADRID and CAMBRIDGE, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 12,673,044, entitled “Methods of treating borderline personality disorder”. The granted claims cover methods of treating non-aggressive symptoms of borderline personality disorder (BPD) using LSD1 inhibitors, including vafidemstat, complementing Oryzon's patent portfolio covering the treatment of aggression....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
